Entry Detail

General Information

Database ID: LDA0004584
Species: Homo sapiens
Confidence Score: 0.731059
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Unknown

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:CASC2
Full Name:cancer susceptibility 2
Category:LncRNA
Species:Homo sapiens
Synonyms:C10orf5
Chromosome:10
Strand:+
Coordinate:
Start Site(bp):118046821End Site(bp):118210153
External Links:
Ensembl ID:ENSG00000177640
Ensembl Transcript ID:N/A
Entrez Gene:255082.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:70   
More Information
Causal Disease Number:60
Network:
Top Causal Diseases:
Carcinoma, Hepatocellular  (Score: 1)
Carcinoma, Hepatocellular  (Score: 1)
Pancreatic Neoplasms  (Score: 0.999893)
Pancreatic Neoplasms  (Score: 0.999893)
Colonic Neoplasms  (Score: 0.985791)
Colonic Neoplasms  (Score: 0.985791)
Thyroid Neoplasms  (Score: 0.985791)
Sepsis  (Score: 0.985791)
Thyroid Neoplasms  (Score: 0.985791)
Arthritis, Rheumatoid  (Score: 0.985791)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:0060060D008228
Disease Name:non-Hodgkin lymphomaLymphoma, Non-Hodgkin
Category:Disease OntologyMeSH
Type:Neoplasms
Define:A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Alias:Lymphoma, Non-Hodgkin//Lymphoma, Non Hodgkin//Lymphoma, Small Cleaved-Cell, Diffuse//Lymphoma, Atypical Diffuse Small Lymphoid//Diffuse Small Cleaved-Cell Lymphoma//Diffuse Small Cleaved Cell Lymphoma//Lymphoma, Small Cleaved Cell, Diffuse//Lymphoma, Nonhodgkins//Nonhodgkins Lymphoma//Lymphoma, Non-Hodgkins//Lymphoma, Non Hodgkins//Non-Hodgkins Lymphoma//Non-Hodgkin's Lymphoma//Non Hodgkin's Lymphoma//Non-Hodgkin Lymphoma//Non Hodgkin Lymphoma//Lymphoma, Nonhodgkin's//Lymphoma, Nonhodgkin//Nonhodgkin's Lymphoma//Small Cleaved-Cell Lymphoma, Diffuse//Small Cleaved Cell Lymphoma, Diffuse//Lymphoma, Non-Hodgkin's//Lymphoma, Non Hodgkin's//Lymphoma, Diffuse//Diffuse Lymphoma//Diffuse Lymphomas//Sarcoma, Lymphatic//Lymphosarcoma//Lymphosarcomas//Lymphatic Sarcoma//Lymphatic Sarcomas//Lymphoma, Low-Grade//Low-Grade Lymphoma//Low-Grade Lymphomas//Lymphoma, Low Grade//Lymphoma, Mixed-Cell//Lymphoma, Mixed Cell//Mixed-Cell Lymphoma//Mixed Cell Lymphoma//Mixed-Cell Lymphomas//Lymphoma, Mixed//Mixed Lymphoma//Mixed Lymphomas//Lymphoma, Mixed Lymphocytic-Histiocytic//Lymphocytic-Histiocytic Lymphoma, Mixed//Lymphocytic-Histiocytic Lymphomas, Mixed//Lymphoma, Mixed Lymphocytic Histiocytic//Mixed Lymphocytic-Histiocytic Lymphoma//Mixed Lymphocytic-Histiocytic Lymphomas//Lymphoma, Non-Hodgkin, Familial//Lymphoma, Small Noncleaved-Cell//Lymphoma, Small Noncleaved Cell//Small Noncleaved-Cell Lymphoma//Noncleaved-Cell Lymphoma, Small//Small Noncleaved Cell Lymphoma//Small Noncleaved-Cell Lymphomas//Diffuse Undifferentiated Lymphoma//Diffuse Undifferentiated Lymphomas//Lymphoma, Diffuse Undifferentiated//Undifferentiated Lymphoma, Diffuse//Lymphoma, Small Non-Cleaved-Cell//Lymphoma, Small Non Cleaved Cell//Non-Cleaved-Cell Lymphoma, Small//Small Non-Cleaved-Cell Lymphomas//Small Non-Cleaved-Cell Lymphoma//Small Non Cleaved Cell Lymphoma//Lymphoma, Undifferentiated, Diffuse//Lymphoma, Intermediate-Grade//Intermediate-Grade Lymphoma//Intermediate-Grade Lymphomas//Lymphoma, Intermediate Grade//Lymphoma, Undifferentiated//Lymphoma, Pleomorphic//Pleomorphic Lymphoma//Pleomorphic Lymphomas//Undifferentiated Lymphoma//Undifferentiated Lymphomas//Reticulum-Cell Sarcoma//Reticulum-Cell Sarcomas//Sarcoma, Reticulum-Cell//Sarcoma, Reticulum Cell//Reticulum Cell Sarcoma//Reticulum Cell Sarcomas//Reticulosarcoma//Reticulosarcomas//Lymphoma, High-Grade//High-Grade Lymphoma//High-Grade Lymphomas//Lymphoma, High Grade//Lymphoma, Mixed-Cell, Diffuse//Mixed Small and Large Cell Lymphoma, Diffuse//Lymphoma, Mixed Small and Large Cell, Diffuse//Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic//Lymphoma, Small and Large Cleaved-Cell, Diffuse//Lymphoma, Mixed Cell, Diffuse//Mixed-Cell Lymphoma, Diffuse//Mixed Cell Lymphoma, Diffuse//Diffuse Mixed Small and Large Cell Lymphoma//Diffuse Mixed-Cell Lymphoma//Diffuse Mixed Cell Lymphoma//Diffuse Mixed-Cell Lymphomas//Lymphoma, Diffuse Mixed-Cell

 

Disease Association Statistics

Total Associated ncRNA Number:6   
More Information
Causal ncRNA Number:2
Network:
Top Causal ncRNAs:
CASC2  (Score: 0.731059)
CASC2  (Score: 0.731059)
More Information

 

Evidence Support

Strong Evidence:Flow Cytometry//qRT-PCR//MTT//Luciferase Report Assay//Transwell Assay
Weak Evidence:

 

Reference

[1] PubMed ID:33283723
Disease Name:Lymphoma, Non-Hodgkin
Sample:cell lines
Dysfunction Pattern:regulation[LncRNA-CASC2/miR-155-5p/APC Axis ]
Validated Method:Flow Cytometry//qRT-PCR//MTT//Luciferase Report Assay//Transwell Assay
Description: CASC2 was downregulated in NHL cell lines.Overexpression of CASC2 suppresses the proliferation and invasion of NK-92 cells, promote the apoptosis of NK-92 cells via targeting miR-155-5p and upregulating APC expression.
Causality:Yes
Causal Description: Overexpression of CASC2 could inhibit the proliferation and invasion of NK-92 cells, and promote its apoptosis.
Clinical-realted Application: